Exclusive: Strand lays off 18% of staff as its first mRNA therapies head into the clinic
Less than a week after announcing that regulators have greenlit the first tests of its tumor-busting mRNA therapy, Strand Therapeutics has laid off roughly 18% of its employees, Endpoints News has learned.
Strand was founded in 2017 based on research of MIT synthetic biologists who figured out how to program on and off switches into mRNA. Those genetic circuits, as they’re called, offered a way to potentially improve the safety and effectiveness of drugs based on the genetic molecules.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.